Site Search:

If you are visiting this website to learn more about the PACT Phase III Study of TNFerade™ in locally advanced pancreatic cancer please click here for information on trial sites and trial participation, call 1-888-344-6096 toll free, or click here to send an e-mail.
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. Each of our product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec’s lead product, TNFerade™, is currently in a pivotal, Phase III clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2.